| Dr Amanda Michael Donohue, DO | |
|
18111 Brookhurst St, #5100, Fountain Valley, CA 92708-6728 | |
| (714) 546-2238 | |
| (714) 434-8145 |
| Full Name | Dr Amanda Michael Donohue |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 19 Years |
| Location | 18111 Brookhurst St, Fountain Valley, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750587143 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 20A9799 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Intermountain Medical Center | Murray, UT | Hospital |
| Lds Hospital | Salt lake city, UT | Hospital |
| Riverton Hospital | Riverton, UT | Hospital |
| Alta View Hospital | Sandy, UT | Hospital |
| Park City Hospital | Park city, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Accumulation of DNA damage can cause aggressive forms of cancer and accelerated aging, so the body's DNA repair mechanisms are normally key to good health. However, in some diseases the DNA repair machinery can become harmful.
Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis.
Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.
As a collaborative effort, the Canadian Red Cross, along with the Canadian International Development Agency, has deployed $1 million of emergency supplies to the flood affected communities in Pakistan. Once in Pakistan, the stocks will be distributed by local volunteers through the Red Cross Red Crescent network.
Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmö have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by studying the risk of VTE in children of parents with VTE compared with the children of parents who have not had VTE.
› Verified 1 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Accumulation of DNA damage can cause aggressive forms of cancer and accelerated aging, so the body's DNA repair mechanisms are normally key to good health. However, in some diseases the DNA repair machinery can become harmful.
Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis.
Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.
As a collaborative effort, the Canadian Red Cross, along with the Canadian International Development Agency, has deployed $1 million of emergency supplies to the flood affected communities in Pakistan. Once in Pakistan, the stocks will be distributed by local volunteers through the Red Cross Red Crescent network.
Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmö have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by studying the risk of VTE in children of parents with VTE compared with the children of parents who have not had VTE.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amanda Michael Donohue, DO 18111 Brookhurst St, #5100, Fountain Valley, CA 92708-6728 Ph: (714) 546-2238 | Dr Amanda Michael Donohue, DO 18111 Brookhurst St, #5100, Fountain Valley, CA 92708-6728 Ph: (714) 546-2238 |
News Archive
Accumulation of DNA damage can cause aggressive forms of cancer and accelerated aging, so the body's DNA repair mechanisms are normally key to good health. However, in some diseases the DNA repair machinery can become harmful.
Cytochroma Inc. today announced results from a Phase Ia clinical study for CTA018, a novel vitamin D analog developed for the treatment of psoriasis.
Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.
As a collaborative effort, the Canadian Red Cross, along with the Canadian International Development Agency, has deployed $1 million of emergency supplies to the flood affected communities in Pakistan. Once in Pakistan, the stocks will be distributed by local volunteers through the Red Cross Red Crescent network.
Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke. Researchers at the Centre for Primary Health Care Research in Malmö have mapped the significance of hereditary factors for venous thromboembolism in the entire Swedish population by studying the risk of VTE in children of parents with VTE compared with the children of parents who have not had VTE.
› Verified 1 days ago
Dr. Kristine Suzanne Olson Arthur, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 11420 Warner Ave, Fountain Valley, CA 92708 Phone: 714-549-1300 Fax: 714-433-3100 | |
Dr. Sajeet Singh Sawhney, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 11100 Warner Ave, Suite 218, Fountain Valley, CA 92708 Phone: 714-641-9696 Fax: 714-641-9696 | |
Dr. Jennifer L Wong, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18111 Brookhurst St Ste 5100, Fountain Valley, CA 92708 Phone: 714-546-2238 Fax: 714-434-8145 | |
Dr. Sithu Lin, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 11100 Warner Ave Ste 218, Fountain Valley, CA 92708 Phone: 714-641-9696 | |
Kien-an Duong, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 11420 Warner Ave, Fountain Valley, CA 92708 Phone: 714-549-1300 Fax: 714-433-3100 | |
Mr. Satinder Swaroop, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 11180 Warner Ave, Suite #353, Fountain Valley, CA 92708 Phone: 714-751-3540 Fax: 714-751-5626 | |
Yu-ming Ni, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 18111 Brookhurst St Ste 5100, Fountain Valley, CA 92708 Phone: 714-546-2238 |